Reported mechanisms include (i) decreased HLA-I [86] and HLA-E [88] expression on MM cell membrane; (ii) TRAIL- and FasL-mediated apoptosis resulting from proteasome-induced increased DR4, DR5, and FAS expression on MM cells [86, 88]; (iii) enhanced NK cell degranulation [86]; and (iv) bortezomib-induced NKG2D and DNAM-1 expression on MM cells, wherein DNAM-1 (CD226) expression is required for mounting optimal immune response against MM cells [87]. The gene discussed is TNFSF10; the disease is Miyoshi myopathy.